Quinazoline derivatives useful as CB-1 inverse agonists
US9682955B2 · kind B2 · utility
0Cited by
1References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 2015 |
| Grant date | Jun 20, 2017 |
| Priority date | — |
| Expiry date | Sep 3, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to quinazoline derivatives, pharmaceutical compositions containing said derivatives and their use in the treatment of disorders and conditions mediated by the CB-1 receptor; more particularly, in the treatment of disorders and conditions responsive to inverse agonism of the CB-1 receptor. For example, the compounds of the present invention are useful in the treatment of metabolic disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.